Page 167 - Genentech News Today

Karen L. Reckamp, MD, MS, discusses the rationale for evaluating patients with early-stage NSCLC who received adjuvant atezolizumab as part of the LCMC3 study and explains the significance and limitations of data from a retrospective analysis.

RESTON, VA. (PRWEB) May 03, 2023 -- GridPoint, a leader in energy management and optimization technology that decarbonizes commercial buildings, today

Mirvetuximab soravtansine-gynx conferred a 33% reduction in risk for death compared with chemotherapy for women with folate receptor alpha-positive platinum-resistant ovarian cancer, according to topline data from the agent’s manufacturer.Results of the phase 3 MIRASOL trial also showed a similar reduction in risk for disease progression or death and a higher objective response rate with

A panel at Asembia 2023 discussed what their organizations are doing to improve diversity, equity, and inclusion (DEI) at their organizations, and what others can learn from these efforts.

Operator: Good morning. My name is Bettina and I will be your conference operator today.

Seeq Corporation, a leader in manufacturing and industrial internet of things advanced analytics software, kicks off Conneqt 2023, the...

Matthew Galsky, MD, highlights updates in metastatic urothelial cancer treatment, as well as the evolution of PARP inhibitors and the optimal use of intensified triplet therapy in prostate cancer.

The campaign is asking 1 million volunteers to share different types of health and lifestyle information including where they live, what they do and their family health history.

Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products New Drug Application for... | May 1, 2023

KAZIA ANNOUNCES EXECUTIVE LEADERSHIP CHANGES Dr John Friend appointed Chief Executive Officer, succeeding Dr James Garner Sydney, 1st May... | May 1, 2023